Investing.comQwen · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 20:36:35·⟳ 抓取 20:37:50 +1m15s·⚡ 决策 08-31 20:55:41 +17m51s·57.1 天前
Lexicon Pharmaceuticals公布索托列净SOLOIST-WHF试验事后血压亚组分析，无新增商业或监管里程碑
这是2020年已发表的SOLOIST-WHF III期试验的事后亚组分析，索托列净（Inpefa）已于2023年FDA获批。事后分析仅确认已知疗效在不同血压亚组中一致，不构成新适应症、新监管申报、新商业化里程碑或收入指引变化。此类学术展示对已上市药物的股价无增量催化作用。
📄 原文Investing.com↗ 原文
Lexicon reports sotagliflozin data across blood pressure ranges
Oil jumps 3% as U.S. strikes on Iran revive Hormuz supply disruption concerns THE WOODLANDS, Texas - Lexicon Pharmaceut…
不做 Lexicon Pharmaceuticals（LXRX.US）
事后亚组分析不改变已获批药物的监管、商业或收入预期，对股价无增量催化。SOLOIST-WHF主结果2020年已公开，索托列净2023年已获批，本次仅为学术再展示。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
SOLOIST-WHF试验主结果2020年发表于NEJM，索托列净2023年获FDA批准上市。本次事件仅为该试验的事后血压亚组切片分析，确认疗效跨亚组一致且无新安全信号——这是对已知数据的学术再展示，不改变监管状态、适应症范围、商业预期或竞争格局。无论股价、市值或流动性如何，此类事件不构成可交易催化。
🔎 新鲜度:最早出现 2026-08-31 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无需先例：事件本身不构成可交易催化，先例研究不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 104 ms
{"result": "search_processed_events:agent query=`lexicon pharmaceuticals sotagliflozin soloist-whf | lxrx blood pressure subgroup analysis esc 2026 | sotagliflozin heart failure jacc`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.7/72 小时、1109 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常
原文全文
展开原文 · 2,000 字
Oil jumps 3% as U.S. strikes on Iran revive Hormuz supply disruption concerns
THE WOODLANDS, Texas - Lexicon Pharmaceuticals (NASDAQ:LXRX) announced results from a post hoc analysis of its Phase 3 SOLOIST-WHF trial examining sotagliflozin in patients recently hospitalized for worsening heart failure across different baseline systolic blood pressure levels. The findings were presented Sunday at ESC Congress 2026 in Munich and published in JACC: Heart Failure, according to a press release statement.
The SOLOIST-WHF trial enrolled 1,222 patients with type 2 diabetes admitted for worsening heart failure, randomizing them to receive sotagliflozin, a dual SGLT 1 and 2 inhibitor, or placebo. The analysis examined treatment effects across the spectrum of baseline systolic blood pressure.
Among 201 patients with baseline systolic blood pressure below 110 mmHg, those receiving sotagliflozin showed a reduction in total occurrences of cardiovascular deaths and heart failure-related events with a hazard ratio of 0.56 (95% CI 0.33-0.95, p=0.03). For the 1,175 patients with baseline systolic blood pressure at or above 110 mmHg, the hazard ratio was 0.69 (95% CI 0.53-0.91, p=0.01).
The analysis found no difference between treatment groups in the incidence of adverse events related to hypotension (p=0.34) or acute kidney injury (p=0.69).
Sotagliflozin is an oral inhibitor of sodium-glucose cotransporter types 2 and 1, proteins involved in glucose regulation. The drug has been studied in approximately 20,000 patients across multiple conditions including heart failure, diabetes, and chronic kidney disease. The company stated sotagliflozin is currently under investigation for hypertrophic cardiomyopathy.
Craig Granowitz, Lexicon’s senior vice president and chief medical officer, stated the results remained consistent across the spectrum of baseline blood pressure in the trial.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
THE WOODLANDS, Texas - Lexicon Pharmaceuticals (NASDAQ:LXRX) announced results from a post hoc analysis of its Phase 3 SOLOIST-WHF trial examining sotagliflozin in patients recently hospitalized for worsening heart failure across different baseline systolic blood pressure levels. The findings were presented Sunday at ESC Congress 2026 in Munich and published in JACC: Heart Failure, according to a press release statement.
The SOLOIST-WHF trial enrolled 1,222 patients with type 2 diabetes admitted for worsening heart failure, randomizing them to receive sotagliflozin, a dual SGLT 1 and 2 inhibitor, or placebo. The analysis examined treatment effects across the spectrum of baseline systolic blood pressure.
Among 201 patients with baseline systolic blood pressure below 110 mmHg, those receiving sotagliflozin showed a reduction in total occurrences of cardiovascular deaths and heart failure-related events with a hazard ratio of 0.56 (95% CI 0.33-0.95, p=0.03). For the 1,175 patients with baseline systolic blood pressure at or above 110 mmHg, the hazard ratio was 0.69 (95% CI 0.53-0.91, p=0.01).
The analysis found no difference between treatment groups in the incidence of adverse events related to hypotension (p=0.34) or acute kidney injury (p=0.69).
Sotagliflozin is an oral inhibitor of sodium-glucose cotransporter types 2 and 1, proteins involved in glucose regulation. The drug has been studied in approximately 20,000 patients across multiple conditions including heart failure, diabetes, and chronic kidney disease. The company stated sotagliflozin is currently under investigation for hypertrophic cardiomyopathy.
Craig Granowitz, Lexicon’s senior vice president and chief medical officer, stated the results remained consistent across the spectrum of baseline blood pressure in the trial.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。